|
|
|
Yale To Sell Research By-Products
Science Park startup tapped as agents for reagents
|
Business New Haven
1/10/2000
By: BNH
|
A New Haven biotech startup founded by a Yale researcher has entered into an agreement with Yale to distribute reagents, which are by-products of research at the university.
Recombinant Technologies LLC, based in Science Park, announced the agreement last month with Yale's Office of Cooperative Research (OCR).
During life-science research at Yale, findings are often published that describe the results and observations obtained using novel biologic reagents, explains OCR Associate Director Ben Muskin. "Some of the biologic reagents, specific to a reported technique or process, can be in immediate high demand by other researchers seeking to repeat and expand upon the reported research," he says.
Yale presently makes the reagents available to non-Yale researchers under what is known as a material transfer agreement, Muskin says. Sometimes the university will enter into a supply or license agreement with a reagent retailer.
Recombinant Technologies, says Muskin, is capable of actively identifying Yale reagents with commercial value and has in place an infrastructure to produce, store, package and ship biologic reagents. It is hoped that the company will have reagents available to the scientific community soon after Yale research is reported in a scholarly journal.
Recombinant founder Pazhani Sundaram is an associate research scientist at Yale's Department of Epidemiology & Public Health. His company, he says, can speed the availability of bulk amounts of by-products by virtue of its close relationships with the academic research community.
Following discovery, Sundaram notes, the publication process can be lengthy. "Useful by-products may not be available for years. The reagents are costly and time-consuming to produce, so a ready source of high quality material immediately available and prepared as specified in the published results would have an instant and significant market value," he says.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
